FromAstraZeneca ([email protected])
Subject (47)Enhertu improved PFS in mBC in DESTINY-Breast02
Preheader (150)Enhertu significantly delayed disease progression in DESTINY-Breast02 Phase III trial vs. physician’s choice of treatment in patients with HER2-positi
Arial
Text Analysis
Body Words248
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px850 px
X-Spam Score-1.9
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeOvernight
